{"id":535529,"date":"2021-09-08T08:06:04","date_gmt":"2021-09-08T12:06:04","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"modified":"2021-09-08T08:06:04","modified_gmt":"2021-09-08T12:06:04","slug":"armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","title":{"rendered":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n MARINA DEL REY, Calif.<\/span>, Sept. 8, 2021<\/span> \/PRNewswire\/ —\u00a0Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021<\/span>.<\/p>\n

\n

\n
\n \"Armata
\n <\/a>\n <\/p>\n<\/p><\/div>\n

The presentation will be available on-demand starting at 7:00 AM ET<\/span> on September 13<\/span>, 2021.\u00a0 If you are an institutional or retail investor, and would like to listen to the Company’s presentation, click HERE<\/a> for the conference.<\/p>\n

\n About Armata Pharmaceuticals, Inc.<\/b>\n <\/p>\n

Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, known as MSD outside of\u00a0the United States\u00a0and\u00a0Canada, Armata is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent. Armata is committed to advancing phage with drug development expertise that spans bench to clinic including in-house phage specific GMP manufacturing.<\/p>\n

\n Media Contacts:<\/b>\n <\/p>\n

\n At Armata:\u00a0
<\/b>Steve Martin\u00a0
Armata Pharmaceuticals, Inc.\u00a0
ir@armatapharma.com<\/a>\u00a0
858-800-2492<\/p>\n

\n Investor Relations:\u00a0
<\/b>Joyce Allaire\u00a0
LifeSci Advisors, LLC\u00a0
jallaire@lifesciadvisors.com<\/a>\u00a0
212-915-2569<\/p>\n

<\/div>\n

\n \"Cision\" View original content to download multimedia:https:\/\/www.prnewswire.com\/news-releases\/armata-pharmaceuticals-to-participate-in-the-hc-wainwright-23rd-annual-global-investment-conference-301371143.html<\/a><\/p>\n

SOURCE Armata Pharmaceuticals, Inc.<\/p>\n<\/p><\/div>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"

PR Newswire MARINA DEL REY, Calif., Sept. 8, 2021 \/PRNewswire\/ —\u00a0Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.\u00a0 If you are an institutional or retail investor, and would like to listen to the Company’s presentation, click HERE for the conference. About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections … <\/p>\n

Continue reading “Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-535529","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nArmata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"PR Newswire MARINA DEL REY, Calif., Sept. 8, 2021 \/PRNewswire\/ —\u00a0Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.\u00a0 If you are an institutional or retail investor, and would like to listen to the Company’s presentation, click HERE for the conference. About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections … Continue reading "Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-08T12:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\",\"datePublished\":\"2021-09-08T12:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"},\"wordCount\":255,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\",\"name\":\"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"datePublished\":\"2021-09-08T12:06:04+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mma.prnewswire.com\\\/media\\\/884786\\\/Armata_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_locale":"en_US","og_type":"article","og_title":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","og_description":"PR Newswire MARINA DEL REY, Calif., Sept. 8, 2021 \/PRNewswire\/ —\u00a0Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on pathogen-specific bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today announced that the Company will participate in the H.C. Wainwright 23rd Annual Global Investment Conference taking place September 13-15, 2021. The presentation will be available on-demand starting at 7:00 AM ET on September 13, 2021.\u00a0 If you are an institutional or retail investor, and would like to listen to the Company’s presentation, click HERE for the conference. About Armata Pharmaceuticals, Inc. Armata is a clinical-stage biotechnology company focused on the development of precisely targeted bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections … Continue reading \"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-08T12:06:04+00:00","og_image":[{"url":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference","datePublished":"2021-09-08T12:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"},"wordCount":255,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/","name":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","datePublished":"2021-09-08T12:06:04+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#primaryimage","url":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg","contentUrl":"https:\/\/mma.prnewswire.com\/media\/884786\/Armata_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/armata-pharmaceuticals-to-participate-in-the-h-c-wainwright-23rd-annual-global-investment-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Armata Pharmaceuticals to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535529","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=535529"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/535529\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=535529"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=535529"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=535529"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}